Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination

Article Medicine, General & Internal

Homologous and Heterologous Covid-19 Booster Vaccinations

R. L. Atmar et al.

Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Covid-19 Vaccine Effectiveness in New York State

Eli S. Rosenberg et al.

Summary: The effectiveness of the BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines in New York State from May to August 2021 was assessed. Initial protection was high, but there was a modest decline in effectiveness after the surge of the delta variant, especially among recipients aged 65 and older. However, protection against hospitalization remained high.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

Shohei Yamamoto et al.

Summary: The study observed that high vaccine reactogenicity after COVID-19 vaccination may be associated with stronger immune responses, and found a correlation between fever after vaccination and higher levels of SARS-CoV-2 spike antibodies.

VACCINE (2022)

Add to Collection

Article Immunology

Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff

Yoshifumi Uwamino et al.

Summary: This study investigated the impact of sex, age, and adverse reactions on antibody response to the BNT162b2 vaccine among Japanese participants. The results showed that female, young, and participants with adverse reactions had higher antibody titers after vaccination.

VACCINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

Anne M. Hause et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers

Si'Ana A. Coggins et al.

Summary: The severity of postvaccination symptoms does not correlate with the magnitude of vaccine-induced antibody levels one month after receiving the Pfizer/BioNTech BNT162b2 vaccine. Additional findings include an inverse correlation between symptoms and age/weight, along with more frequent systemic symptoms after the second vaccination and lower antibody titers in older individuals.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study

Cristina Menni et al.

Summary: This study aimed to investigate the effectiveness and waning of COVID-19 primary vaccine series, as well as the safety and effectiveness of booster doses. The results showed that vaccine effectiveness decreased after the second dose, but booster doses restored effectiveness. However, heterologous booster regimens had more systemic side-effects.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Edson D. Moreira et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study

Daisuke Jubishi et al.

Summary: This prospective observational cohort study found that adverse reactions after vaccination with COVID-19 mRNA vaccines are common, but the association between adverse reactions and humoral immune responses is uncertain. The study also found that a history of asthma and stronger reactions after the second dose were positively associated with elevated anti-spike IgG levels.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Article Immunology

Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination Jane

Jane A. Dickerson et al.

Summary: This study analyzed immune responses to SARS-CoV-2 vaccines in healthcare workers. Factors such as age, time, and vaccine reactogenicity were found to be associated with the magnitude and durability of the response. The study observed higher antibody responses in participants who experienced symptoms after the second dose of the vaccine. Age and sex did not have an impact on antibody levels.

VACCINES (2022)

Add to Collection

Article Immunology

Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up

Andrea Kanizsai et al.

Summary: This study investigates the relationship between post-vaccination adverse reactions and antibody levels. The results suggest that fever may play an important role in the long-term immune response.

VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records

Michiel J. M. Niesen et al.

Summary: This study evaluated the safety of the third dose of FDA-approved COVID-19 mRNA vaccines. The findings suggest that although the third dose is associated with an increased reporting of low-severity adverse events, the risk of severe adverse events remains comparable to the standard two-dose regime. This study provides evidence for the safety of third vaccination doses in eligible individuals for booster vaccination.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Immunology

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis

Ting-Yun Lin et al.

Summary: This study aimed to investigate the relationship between local and systemic reactions following SARS-CoV-2 vaccination and immunogenicity in patients undergoing hemodialysis. The study found that patients who reported stronger local and systemic reactions were more likely to develop an antibody response. These patients were younger, had a lower prevalence of coronary artery disease and use of immunosuppressants, and had a higher body mass index and lymphocyte count.

VACCINES (2022)

Add to Collection

Article Infectious Diseases

A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization

David Peterhoff et al.

Summary: The study developed a specific and sensitive enzyme linked immunosorbent assay (ELISA) for detection of anti-SARS-CoV-2 antibody levels. The ELISA showed high specificity and strong correlation in detecting SARS-CoV-2 antibodies, and was able to generate robust antibody levels 10 days after symptom onset.

INFECTION (2021)

Add to Collection

Article Immunology

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2

Stilla Bauernfeind et al.

Summary: This study found that severe adverse reactions after vaccination with the BNT162b2 vaccine can significantly impact humoral immune response in men, but not in women or T-cell-mediated immune response.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests-A Population-Based Evaluation

Sebastian Einhauser et al.

Summary: This study compared the performance of different antibody testing methods in a population-based setting and found that spectrum bias could affect the sensitivity and specificity of the tests, with varying quantitative correlations between different test methods. The two Roche anti-SARS-CoV-2 tests outperformed others in sensitivity and specificity in a population-based setting, but showed discrepancies in quantitative correlation with neutralization capacity.

DIAGNOSTICS (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Masaaki Takeuchi et al.

Summary: The severity of reactions after the second dose of the mRNA vaccine BNT162b2 may not accurately reflect antibody production levels. While spike IgG levels were correlated with age and levels after the first dose, adverse event scores were not significantly associated with log-transformed spike IgG levels after the second dose.

PLOS ONE (2021)

Add to Collection

Article Medicine, General & Internal

Can reactogenicity predict immunogenicity after COVID-19 vaccination?

Young Hoon Hwang et al.

Summary: This study found no significant association between the severity of local and systemic adverse events and humoral immunogenicity after SARS-CoV-2 vaccination.

KOREAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Catherine M. Brown et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Immunology

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response

Yoav Rechavi et al.

Summary: Adverse reactions to the BNT162b2 vaccine are associated with enhanced antibody response, potentially aiding in reducing vaccination hesitancy.

VACCINES (2021)

Add to Collection

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Biochemistry & Molecular Biology